Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Soligenix Develops Defenses Against Bioterrorism SNGX

Share on Stocktwits


Maxim Group biotech analyst Jason Kolbert notes "steady progress" is being made by Soligenix Inc., a small-cap biotech with programs addressing bioterrorism threats and a devastating side effect of cancer treatment, in his Q1/16 update on the company.

[Editor's Note: The following has been excerpted from a Maxim Group research report. Click here to read the entire report.]

Soligenix Inc. (SNGX:OTCQB) reported Q1/16 results with total revenues of $2.6M, including contract revenues from BARDA (Biomedical Advanced Research and Development Authority) and NIAID (National Institute of Allergy and Infectious Diseases) for development of OrbeShield and ThermoVax combined with RiVax. Net loss for the quarter was $1.1M or $(0.04) per share and the company ended the period with $4.3M in cash.

The company released positive data from the Phase 2 oral mucositis study with SGX942 this past quarter. SGX942's novel mechanism of action as an Innate Defense Regulator showed the potential to address all stages of oral mucositis disease progression. The company is currently in talks with the US and EU regulatory authorities and expects to initiate a pivotal Phase 2b/3 study before the year-end.

Soligenix continues to enroll patients for the pivotal Phase 3 study in cutaneous T-cell lymphoma with SGX301 (synthetic hypericin). Enrollment is expected to complete in H2/16. . .

The positive preliminary results of the SGX942 Phase 2 study sets the stage for Soligenix to pursue partnerships for the Phase 2/3 study. We are excited for the potential of this molecule to really have an impact in an area that represents a truly unmet medical need.

Kolbert has issued a 12-month target price of $3 per share.

Want to read more Life Sciences Report interviews like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent interviews with industry analysts and commentators, visit our Streetwise Interviews page.

1) Soligenix Inc. is a sponsor of Streetwise Reports. Soligenix Inc. was not involved in any aspect of the article preparation. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
2) Tracy Salcedo compiled this article for Streetwise Reports LLC. She provides services to Streetwise Reports as an employee. She owns, or her family owns, shares of the following companies mentioned in this interview: None.
3) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
4) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their families are prohibited from making purchases and/or sales of those securities in the open market or otherwise during the up-to-four-week interval from the time of the interview until after it publishes.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe